← Back to Screener
Syndax Pharmaceuticals, Inc. (SNDX)
Price$18.85
Value ScoreD
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-1.03%
Price vs S&P 500 (4W)-2.46%
VGM Score57.72
Market Capitalization$1.74B
All Metrics
Book Value / Share (Quarterly)$0.74
P/TBV (Annual)2.31x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-44.66%
Cash Flow / Share (Quarterly)$-3.70
Price vs S&P 500 (YTD)-17.69%
Gross Margin (TTM)95.96%
Net Profit Margin (TTM)-165.37%
EPS (TTM)$-3.30
10-Day Avg Trading Volume1.13M
EPS Excl Extra (TTM)$-3.30
Revenue Growth (5Y)158.26%
EPS (Annual)$-3.29
ROI (Annual)-69.86%
Gross Margin (Annual)95.96%
Net Profit Margin (5Y Avg)-2021.44%
Cash / Share (Quarterly)$4.73
Revenue Growth QoQ (YoY)794.90%
ROA (Last FY)-53.88%
Revenue Growth TTM (YoY)628.88%
EBITD / Share (TTM)$-3.16
ROE (5Y Avg)-123.17%
Operating Margin (TTM)-158.22%
Cash Flow / Share (Annual)$-3.70
P/B Ratio26.86x
P/B Ratio (Quarterly)28.25x
Net Income / Employee (Annual)$-957,800
EV / Revenue (TTM)11.27x
Net Interest Coverage (TTM)-24.82x
ROA (TTM)-49.25%
EV / EBITDA (TTM)1721.11x
EPS Incl Extra (Annual)$-3.29
Current Ratio (Annual)4.40x
Quick Ratio (Quarterly)4.04x
3-Month Avg Trading Volume1.46M
52-Week Price Return84.46%
Revenue / Employee (TTM)$579,200
Tangible BV / Share (Quarterly)$5.16
P/S Ratio (Annual)10.07x
Asset Turnover (Annual)0.33x
52-Week High$25.59
Operating Margin (5Y Avg)-2033.49%
EPS Excl Extra (Annual)$-3.29
Tangible BV CAGR (5Y)34.98%
26-Week Price Return14.90%
Quick Ratio (Annual)4.04x
13-Week Price Return-5.22%
Total Debt / Equity (Annual)5.32x
Current Ratio (Quarterly)4.40x
Enterprise Value$1.94B
Revenue / Share Growth (5Y)122.73%
Asset Turnover (TTM)0.30x
Book Value / Share Growth (5Y)-32.47%
Revenue / Employee (Annual)$578,400
Pretax Margin (Annual)-165.60%
Cash / Share (Annual)$4.73
3-Month Return Std Dev47.80%
Net Income / Employee (TTM)$-957,800
ROE (Last FY)-441.62%
Net Interest Coverage (Annual)-24.82x
EPS Basic Excl Extra (Annual)$-3.29
Receivables Turnover (TTM)7.57x
Total Debt / Equity (Quarterly)5.32x
EPS Incl Extra (TTM)$-3.30
ROI (TTM)-59.13%
P/S Ratio (TTM)10.06x
Pretax Margin (5Y Avg)-2021.44%
Revenue / Share (Annual)$1.99
Tangible BV / Share (Annual)$6.86
Price vs S&P 500 (52W)56.26%
Year-to-Date Return-6.76%
5-Day Price Return-1.76%
EPS Normalized (Annual)$-3.29
ROA (5Y Avg)-31.30%
Net Profit Margin (Annual)-165.60%
Month-to-Date Return-8.59%
Cash Flow / Share (TTM)$-2.59
EBITD / Share (Annual)$-3.15
Operating Margin (Annual)-158.45%
LT Debt / Equity (Annual)5.32x
ROI (5Y Avg)-36.84%
LT Debt / Equity (Quarterly)5.32x
EPS Basic Excl Extra (TTM)$-3.30
P/TBV (Quarterly)3.01x
P/B Ratio (Annual)28.25x
Inventory Turnover (TTM)0.42x
Pretax Margin (TTM)-165.37%
Book Value / Share (Annual)$0.74
Price vs S&P 500 (13W)-14.97%
Beta0.38x
P/FCF (Annual)59.86x
Revenue / Share (TTM)$1.99
ROE (TTM)-206.62%
52-Week Low$8.59
vGradeD
gGradeA
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.48est. -0.59
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.35
4.35
4.35
4.35
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SNDXSyndax Pharmaceuticals, Inc. | D | A | C | $18.85 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cancer and immune-related diseases. Its pipeline includes revumenib, a selective menin-MLL inhibitor for acute leukemias; axatilimab, a CSF-1R antibody for chronic graft-versus-host disease and pulmonary fibrosis; and entinostat, an oral small molecule targeting cancer cells and immune cells. The company is based in the United States.